Therapeutic agents inhibiting pro-fibrotic TGF-β1/Smad2/3 signaling could prevent renal fibrosis 94, liver fibrosis 95, 96, pulmonary fibrosis 97, 98, and cardiac fibrosis 99-101. Here, SMAD2 is linked to renal fibrosis.